Clinical Trial

LGG Supplementation in Patients With AUD and ALD

Study acronym: AUD+ALD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To test the efficacy of 6-month LGG compared to placebo in treating Alcoholic Use Disorder (AUD) and liver injury in Alcoholic Hepatitis (AH). And to evaluate the effects of LGG treatment compared to placebo on therapeutic-mechanistic markers of the gut-brain axis and pro-inflammatory activity in patients with AUD and moderate AH
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2021-12-15; most recent amendment 2025-10-29.
Status change: Not Yet Recruiting → Recruiting 2022-10-21
Trial Details
NCT Number NCT05178069
Lead Sponsor University of Louisville
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions Alcohol Use Disorder, Alcohol-associated Liver Disease
Enrollment 60 participants
Start Date 2022-06-01
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-10-31